/
BOLT
$3.91-$0.37 (-8.66%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$8.2M
2M shares
52-week range
$3.75 – $7.20
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-305.30
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $215.0K | $231.0K | $1.3M | $5.7M | $7.9M | $7.7M | $7.7M |
| Cost of revenue | $302.0K | $0 | $40.4M | $75.7M | $73.1M | $61.5M | $0 | $1.5M |
| Gross profit | −$302.0K | $215.0K | −$40.1M | −$74.4M | −$67.4M | −$53.7M | $7.7M | $6.2M |
| Gross margin | — | 100.0% | -17370.6% | -5904.4% | -1176.4% | -681.4% | 100.0% | 80.6% |
| R&D | $9.4M | $26.0M | $40.4M | $75.7M | $73.1M | $61.5M | $57.5M | $28.5M |
| Operating income | −$11.6M | −$31.0M | −$49.2M | −$92.8M | −$90.3M | −$76.2M | −$73.0M | −$34.6M |
| EBITDA | −$11.3M | −$30.6M | −$48.6M | −$97.4M | −$86.4M | −$67.3M | −$66.5M | −$31.9M |
| Net income | −$11.6M | −$30.5M | −$60.7M | −$98.6M | −$88.1M | −$69.2M | −$63.1M | −$33.4M |
| Net margin | — | -14180.0% | -26289.2% | -7824.7% | -1537.8% | -878.6% | -820.8% | -433.7% |
| EPS (diluted) | -5.96 | -3.75 | -1.99 | -2.79 | -2.30 | -1.83 | -1.65 | -17.85 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-15.88 | $-15.88–$-15.88 | 2 |
| 2027 | $2M | $-19.93 | $-38.68–$-1.18 | 2 |
| 2028 | $4M | $-30.84 | $-30.84–$-30.84 | 1 |
| 2029 | $4M | $-35.53 | $-35.53–$-35.53 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Bolt Biotherapeutics, Inc. Common Stock
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
www.boltbio.com- Employees
- 23
- IPO / List date
- Feb 5, 2021
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds BOLT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 77,225 | $312.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-09 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded BOLT yet.
